JP2020503376A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020503376A5 JP2020503376A5 JP2019551918A JP2019551918A JP2020503376A5 JP 2020503376 A5 JP2020503376 A5 JP 2020503376A5 JP 2019551918 A JP2019551918 A JP 2019551918A JP 2019551918 A JP2019551918 A JP 2019551918A JP 2020503376 A5 JP2020503376 A5 JP 2020503376A5
- Authority
- JP
- Japan
- Prior art keywords
- enantiomer
- salt
- mixture
- pharmaceutical composition
- lower alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229910052739 hydrogen Inorganic materials 0.000 claims 14
- 239000001257 hydrogen Substances 0.000 claims 14
- 239000000203 mixture Substances 0.000 claims 14
- 150000003839 salts Chemical class 0.000 claims 14
- 125000003545 alkoxy group Chemical group 0.000 claims 11
- 239000008194 pharmaceutical composition Substances 0.000 claims 11
- 125000000217 alkyl group Chemical group 0.000 claims 10
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 8
- 150000001875 compounds Chemical class 0.000 claims 8
- 125000003342 alkenyl group Chemical group 0.000 claims 7
- 150000002431 hydrogen Chemical class 0.000 claims 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 6
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 6
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 6
- 125000001424 substituent group Chemical group 0.000 claims 6
- 208000023275 Autoimmune disease Diseases 0.000 claims 4
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims 4
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 4
- 208000034943 Primary Sjögren syndrome Diseases 0.000 claims 4
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 4
- 206010042953 Systemic sclerosis Diseases 0.000 claims 4
- 208000016025 Waldenstroem macroglobulinemia Diseases 0.000 claims 4
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims 4
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 4
- 229910052805 deuterium Inorganic materials 0.000 claims 4
- -1 methoxy, ethoxy, propyloxy Chemical group 0.000 claims 4
- 201000006417 multiple sclerosis Diseases 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- 210000004214 philadelphia chromosome Anatomy 0.000 claims 4
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 4
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 4
- 102000001253 Protein Kinase Human genes 0.000 claims 3
- 229910052799 carbon Inorganic materials 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 229910052736 halogen Inorganic materials 0.000 claims 3
- 150000002367 halogens Chemical class 0.000 claims 3
- 230000001404 mediated effect Effects 0.000 claims 3
- 108060006633 protein kinase Proteins 0.000 claims 3
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 2
- 208000034578 Multiple myelomas Diseases 0.000 claims 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 206010042971 T-cell lymphoma Diseases 0.000 claims 2
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims 2
- 206010052779 Transplant rejections Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 150000001721 carbon Chemical group 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 201000003444 follicular lymphoma Diseases 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 201000007924 marginal zone B-cell lymphoma Diseases 0.000 claims 2
- 208000021937 marginal zone lymphoma Diseases 0.000 claims 2
- 201000000050 myeloid neoplasm Diseases 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 241000023320 Luma <angiosperm> Species 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 229960003444 immunosuppressant agent Drugs 0.000 claims 1
- 230000001861 immunosuppressant effect Effects 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662433410P | 2016-12-13 | 2016-12-13 | |
| US62/433,410 | 2016-12-13 | ||
| US201762539785P | 2017-08-01 | 2017-08-01 | |
| US62/539,785 | 2017-08-01 | ||
| PCT/US2017/065847 WO2018111893A1 (en) | 2016-12-13 | 2017-12-12 | Protein kinase inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020503376A JP2020503376A (ja) | 2020-01-30 |
| JP2020503376A5 true JP2020503376A5 (enExample) | 2020-11-12 |
| JP7077335B2 JP7077335B2 (ja) | 2022-05-30 |
Family
ID=61829613
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019551918A Active JP7077335B2 (ja) | 2016-12-13 | 2017-12-12 | プロテインキナーゼ阻害剤 |
Country Status (8)
| Country | Link |
|---|---|
| US (5) | US10479786B2 (enExample) |
| EP (1) | EP3555092A4 (enExample) |
| JP (1) | JP7077335B2 (enExample) |
| KR (1) | KR102582752B1 (enExample) |
| CN (1) | CN108473487B (enExample) |
| AU (1) | AU2017375949B2 (enExample) |
| CA (1) | CA3044066A1 (enExample) |
| WO (1) | WO2018111893A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10479786B2 (en) | 2016-12-13 | 2019-11-19 | Princeton Drug Discovery, Inc | Protein kinase inhibitors |
| EP3846793B1 (en) | 2018-09-07 | 2024-01-24 | PIC Therapeutics, Inc. | Eif4e inhibitors and uses thereof |
| WO2020123277A1 (en) * | 2018-12-10 | 2020-06-18 | Princeton Drug Discovery Inc. | Protein kinase inhibitor prodrugs |
| KR102256804B1 (ko) * | 2019-02-26 | 2021-05-26 | 한국화학연구원 | N-페닐-2-(피리미딘-4-일아미노)티아졸-5-카복사미드 유도체, 이의 약학적으로 허용 가능한 염 및 이를 유효성분으로 함유하는 미백 소재 조성물 |
| AU2021230289A1 (en) | 2020-03-03 | 2022-09-29 | PIC Therapeutics, Inc. | eIF4E inhibitors and uses thereof |
| CA3229560A1 (en) | 2021-08-25 | 2023-03-02 | Christopher L. Vandeusen | Eif4e inhibitors and uses thereof |
| JP2024532276A (ja) | 2021-08-25 | 2024-09-05 | ピク セラピューティクス， インコーポレイテッド | ｅＩＦ４Ｅ阻害剤及びその使用 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2308833A3 (en) | 1999-04-15 | 2011-09-28 | Bristol-Myers Squibb Company | Cyclic protein tyrosine kinase inhibitors |
| US7125875B2 (en) | 1999-04-15 | 2006-10-24 | Bristol-Myers Squibb Company | Cyclic protein tyrosine kinase inhibitors |
| ES2257461T3 (es) | 2000-12-21 | 2006-08-01 | Bristol-Myers Squibb Company | Inhibidores de tiazolilo de tirosina quinasas de la familia tec. |
| TW200501960A (en) | 2002-10-02 | 2005-01-16 | Bristol Myers Squibb Co | Synergistic kits and compositions for treating cancer |
| US20040209930A1 (en) * | 2002-10-02 | 2004-10-21 | Carboni Joan M. | Synergistic methods and compositions for treating cancer |
| US7491725B2 (en) | 2004-02-06 | 2009-02-17 | Bristol-Myers Squibb Company | Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors |
| US20060021105A1 (en) * | 2004-07-29 | 2006-02-02 | Wilson Nick L | Ergonomic hand protection apparatus |
| PE20061394A1 (es) | 2005-03-15 | 2006-12-15 | Bristol Myers Squibb Co | Metabolitos de n-(2-cloro-6-metilfenil)-2-[[6-[4-(2-hidroxietil)-1-piperazinil]-2-metil-4-pirimidinil]amino]-5-tiazolcarboxamidas |
| KR101433629B1 (ko) * | 2006-09-11 | 2014-08-27 | 쿠리스 인코퍼레이션 | 아연 결합 부분을 함유한 티로신 키나아제 억제제 |
| TW200906825A (en) | 2007-05-30 | 2009-02-16 | Scripps Research Inst | Inhibitors of protein kinases |
| US20090076025A1 (en) * | 2007-09-14 | 2009-03-19 | Protia, Llc | Deuterium-enriched dasatinib |
| ES2396366T3 (es) | 2007-12-10 | 2013-02-21 | Concert Pharmaceuticals Inc. | Inhibidores heterocíclicos de quinasas |
| US8563554B2 (en) | 2009-03-17 | 2013-10-22 | Concert Pharmaceuticals, Inc. | Deuterated pyrazinoisoquinoline compounds |
| WO2010144338A1 (en) * | 2009-06-08 | 2010-12-16 | Abraxis Bioscience, Llc | Triazine derivatives and their therapeutical applications |
| CA2775155A1 (en) * | 2009-10-01 | 2011-04-07 | Csl Limited | Method of treatment of philadelphia chromosome positive leukemia |
| CN101891738B (zh) | 2010-02-08 | 2011-09-28 | 南京卡文迪许生物工程技术有限公司 | 达沙替尼多晶型物及其制备方法和药用组合物 |
| NZ717373A (en) | 2010-06-03 | 2017-11-24 | Pharmacyclics Llc | The use of inhibitors of bruton’s tyrosine kinase (btk) |
| EP2872159A2 (en) | 2012-07-13 | 2015-05-20 | Concert Pharmaceuticals Inc. | Deuterated carfilzomib |
| MX2015012610A (es) | 2013-03-14 | 2016-02-17 | Concert Pharmaceuticals Inc | Pacritinib deuterizado. |
| CN104130250B (zh) | 2013-05-07 | 2016-06-22 | 郑州泰基鸿诺药物科技有限公司 | 氘代达沙替尼及其制备方法和应用 |
| CN104151321B (zh) | 2013-05-15 | 2016-09-07 | 复旦大学 | N-(2-氯-6-甲基苯基)-2[(2-甲基嘧啶-4-基)氨基]噻唑-5-甲酰胺化合物及其制备方法和用途 |
| IL311537A (en) | 2014-01-28 | 2024-05-01 | Mayo Found Medical Education & Res | Methods and preparations for killing aging cells and for the treatment of diseases and disorders related to aging |
| US20170224688A1 (en) | 2016-02-04 | 2017-08-10 | Acerta Pharma B.V. | Methods of Using BTK Inhibitors to Treat Dermatoses |
| WO2017168454A2 (en) * | 2016-04-02 | 2017-10-05 | Sun Pharma Advanced Research Company Limited | Novel compounds as btk inhibitors |
| US10479786B2 (en) * | 2016-12-13 | 2019-11-19 | Princeton Drug Discovery, Inc | Protein kinase inhibitors |
-
2017
- 2017-12-12 US US15/839,469 patent/US10479786B2/en active Active
- 2017-12-12 CN CN201780002746.8A patent/CN108473487B/zh active Active
- 2017-12-12 KR KR1020197018970A patent/KR102582752B1/ko active Active
- 2017-12-12 US US15/839,332 patent/US10174018B2/en active Active
- 2017-12-12 JP JP2019551918A patent/JP7077335B2/ja active Active
- 2017-12-12 EP EP17879997.9A patent/EP3555092A4/en active Pending
- 2017-12-12 AU AU2017375949A patent/AU2017375949B2/en active Active
- 2017-12-12 CA CA3044066A patent/CA3044066A1/en active Pending
- 2017-12-12 US US15/839,534 patent/US20180099961A1/en not_active Abandoned
- 2017-12-12 WO PCT/US2017/065847 patent/WO2018111893A1/en not_active Ceased
-
2018
- 2018-11-02 US US16/179,174 patent/US10556897B2/en active Active
-
2019
- 2019-12-19 US US16/721,142 patent/US11236080B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020503376A5 (enExample) | ||
| RU2468021C2 (ru) | Гетероциклические соединения и их применение | |
| IL278297B1 (en) | Transmutable heterocyclic ptpn11 inhibitors | |
| JP2008528467A5 (enExample) | ||
| RU2018138828A (ru) | Уменьшение массы опухоли путем введения ccr1 антагонистов в комбинации с pd-1 ингибиторами или pd-l1 ингибиторами | |
| CN107548391A (zh) | 嘧啶或吡啶类化合物、其制备方法和医药用途 | |
| JP2009513703A5 (enExample) | ||
| JP2020506951A5 (enExample) | ||
| JP2008505167A5 (enExample) | ||
| JP2020524719A5 (enExample) | ||
| CN109803972A (zh) | 1H-咪唑[4,5-h]喹唑啉类化合物作为蛋白激酶抑制剂 | |
| JP2009536620A5 (enExample) | ||
| US11976064B2 (en) | Toll-like receptor agonists | |
| CA2455181A1 (en) | Benzimidazo[4,5-f]isoquinolinone derivatives | |
| EA021421B1 (ru) | Производные хинолинов и хиноксалинов в качестве ингибиторов протеинтирозинкиназы, способ их получения, содержащая их фармацевтическая композиция и способ лечения заболеваний с применением таких соединений | |
| JP2018507877A5 (enExample) | ||
| JP2019513743A (ja) | インドールアミン ２，３−ジオキシゲナーゼ阻害剤、その製造方法及び応用 | |
| CN109906227A (zh) | 8,9-二氢咪唑[1,2-a]嘧啶并[5,4-e]嘧啶-5(6H)-酮类化合物 | |
| CN106660974A (zh) | 含氨磺酰基的1,2,5‑噁二唑类衍生物、其制备方法及其在医药上的应用 | |
| JP2007538092A5 (enExample) | ||
| JP2008535902A5 (enExample) | ||
| JP2015535851A5 (enExample) | ||
| RU2016118753A (ru) | Производные пиридилкетона, способ их получения и их фармацевтическое применение | |
| JP2011506402A5 (enExample) | ||
| RU2018102963A (ru) | Производные анилинпиримидина и их применения |